Nasdaq · CIK 0000025743
TXMD TherapeuticsMD, Inc.
Insider trading from SEC Form 4. Last filing Dec 29, 2025. Close $2.06 on Oct 9, 2026, +98% from the 52-week low and -26% from the high.
TherapeuticsMD, Inc. (TXMD) has 9 SEC Form 4 filings on file from 4 insiders, the latest filed on Dec 29, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at TXMD. The newest: Tommy G Thompson (director) bought $14k of stock on Dec 23, 2025, filed Dec 29, 2025, scored 25 (weak). 2 insiders bought within 14 days of each other around Apr 14, 2025.
TXMD closed at $2.06 on Oct 9, 2026, 98% above its 52-week low and 26% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at TherapeuticsMD, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Tommy G Thompson director buy | $14k 8,400 shares | +57% | - | |
| 33Weak | Marlan D Walker Chief Executive Officer buy | $489 490 shares | +1% | - | |
| 23Weak | Tommy G Thompson director buy | $326 325 shares | +2% | - | |
| 33Weak | Marlan D Walker Chief Executive Officer buy | $1,994 2,303 shares | +3% | - |
Transactions
Every row filed, 11 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Tommy G Thompson director | POpen-market purchase Common Stock | +8,400 | $1.67 | $14k | 23,179 | Dec 29, 2025 |
| Nov 3, 2025 | Cooper C. Collins director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | Nov 5, 2025 |
| Nov 3, 2025 | Gail K Naughton director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | Nov 5, 2025 |
| Nov 3, 2025 | Marlan D Walker Chief Executive Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +67,492 | $0.00 | $0 | 67,492 | Nov 5, 2025 |
| Nov 3, 2025 | Tommy G Thompson director | AGrant or award Restricted Stock Unitsderivative | +8,500 | $0.00 | $0 | 8,500 | Nov 5, 2025 |
| Apr 14, 2025 | Marlan D Walker Chief Executive Officer | POpen-market purchase Common Stock | +490 | $1.00 | $489 | 73,639 | Apr 15, 2025 |
| Apr 14, 2025 | Tommy G Thompson director | POpen-market purchase Common Stock | +325 | $1.00 | $326 | 14,779 | Apr 15, 2025 |
| Apr 9, 2025 | Marlan D Walker Chief Executive Officer | POpen-market purchase Common Stock | +1,136 | $0.87 | $994 | 71,982 | Apr 10, 2025 |
| Apr 10, 2025 | Marlan D Walker Chief Executive Officer | POpen-market purchase Common Stock | +1,167 | $0.86 | $1,000 | 73,149 | Apr 10, 2025 |
| Feb 18, 2025 | Cooper C. Collins director | MOption exercise Common Stock | +8,500 | $0.00 | $0 | 60,516 | Feb 20, 2025 |
| Feb 18, 2025 | Cooper C. Collins director | MOption exercise Restricted Stock Unitsderivative | -8,500 | $0.00 | $0 | 0 | Feb 20, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Cooper C. Collinsdirector
- Gail K Naughtondirector
- Tommy G Thompsondirector
- Marlan D WalkerChief Executive Officer
Questions about TXMD
Answered from the filings on this page, as of the latest one.
Are insiders buying TXMD?
No. In the last 90 days no insider at TherapeuticsMD, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TXMD on the open market?
Tommy G Thompson (director) bought $14k of TXMD on Dec 23, 2025 and filed the Form 4 on Dec 29, 2025. InsiderTell scored 25 (weak).
How many insiders file Form 4 at TherapeuticsMD, Inc.?
4 people have filed a Form 4 at TherapeuticsMD, Inc., among them Cooper C. Collins (director), Gail K Naughton (director), Tommy G Thompson (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.